Severity of illness models for respiratory syncytial virus-associated hospitalization.

The objective of this investigation was to examine the feasibility of multivariate severity of illness models for pediatric patients hospitalized with respiratory syncytial virus (RSV) infection. From a preexisting retrospective cohort study database, all infants and children 2 yr of age or younger with community-acquired RSV infection admitted to the University of Michigan's C. S. Mott Children's Hospital during nine epidemics were examined. The study group consisted of 802 hospitalized patients younger than 2 yr of age with community-acquired RSV infection; 182 (23%) patients had prolonged hospital length of stay defined as 7 d or greater. Multivariate logistic regression modeling of nine variables measurable during the first hospital day was strongly associated with prolonged hospitalization (p < 0.0001). Receiver operator characteristic curve analysis resulted in an area under the curve of 0.894, indicating excellent model discrimination. Goodness-of-fit testing indicated excellent model calibration for observed versus predicted outcomes (p = 0.216). We conclude that severity of illness models for RSV-associated hospitalization with excellent predictive properties in terms of classification, discrimination, and calibration are possible. Further study is required to determine if such models are generalizable across multiple centers and epidemics.

[1]  L. Wright,et al.  Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV , 1998, Pediatrics.

[2]  W. Dankner Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis , 1997, Pediatrics.

[3]  E. Wang,et al.  Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. , 1997, The Journal of pediatrics.

[4]  L. Wright,et al.  Respiratory syncytial virus immune globulin intravenous: Indications for use , 1997 .

[5]  W. Gruber,et al.  Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections , 1997 .

[6]  A. Laupacis,et al.  Clinical prediction rules. A review and suggested modifications of methodological standards. , 1997, JAMA.

[7]  A. Monto,et al.  Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. , 1996, Journal of clinical epidemiology.

[8]  E. Simões,et al.  RESPIRATORY SYNCYTIAL VIRUS IMMUNOGLOBULIN AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS IN CHILDREN WITH CONGENITAL HEART DISEASE. • 662 , 1996, Pediatric Research.

[9]  S. Ohmit,et al.  Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group. , 1996, The Journal of pediatrics.

[10]  R. Jacobs,et al.  Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. , 1996, Pediatrics.

[11]  S. Lemeshow,et al.  Modeling the Severity of Illness of ICU Patients: A Systems Update , 1995 .

[12]  E. Wang,et al.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. , 1995, The Journal of pediatrics.

[13]  S. Lemeshow,et al.  Modeling the severity of illness of ICU patients. A systems update. , 1994, JAMA.

[14]  Matthew Gelmini,et al.  Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double‐blind, randomized trial , 1994, Critical care medicine.

[15]  U. Ruttimann,et al.  Statistical approaches to development and validation of predictive instruments. , 1994, Critical care clinics.

[16]  C. Hall,et al.  Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children , 1993 .

[17]  R. Turner,et al.  Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. , 1993, The Pediatric infectious disease journal.

[18]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[19]  D. W. Smith,et al.  A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. , 1991, The New England journal of medicine.

[20]  S. Heidemann,et al.  Does prematurity alter the course of respiratory syncytial virus infection? , 1990, Critical care medicine.

[21]  C. Hall,et al.  Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. , 1990, The Journal of pediatrics.

[22]  U. Ruttimann,et al.  Pediatric risk of mortality (PRISM) score. , 1988, Critical care medicine.

[23]  K. Gutierrez,et al.  Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. , 1988, Pediatrics.

[24]  P. Getson,et al.  Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease , 1987, The Pediatric infectious disease journal.

[25]  C B Hall,et al.  Respiratory syncytial viral infection in children with compromised immune function. , 1986, The New England journal of medicine.

[26]  R. Cornall,et al.  Ribavirin aerosol for acute bronchiolitis. , 1986, Archives of disease in childhood.

[27]  C. Hall,et al.  Ribavirin Treatment of Respiratory Syncytial Viral Infection in Infants With Underlying Cardiopulmonary Disease , 1985 .

[28]  V. Knight,et al.  Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. , 1983, Pediatrics.

[29]  E. Walsh,et al.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. , 1983, The New England journal of medicine.

[30]  C. Hall,et al.  Respiratory syncytial viral infection in infants with congenital heart disease. , 1982, The New England journal of medicine.

[31]  R. Douglas,et al.  Nosocomial respiratory syncytial virus infections. , 1975, The New England journal of medicine.

[32]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.